



Published in final edited form as:

*Pediatr Res.* 2017 November ; 82(5): 855–862. doi:10.1038/pr.2017.157.

## Foxd1 is an upstream regulator of the renin–angiotensin system during metanephric kidney development

Renfang Song<sup>1</sup>, Maria Luisa S. Sequeira Lopez<sup>2</sup>, and Ihor V. Yosypiv<sup>1</sup>

<sup>1</sup>Division of Pediatric Nephrology, Department of Pediatrics, Hypertension and Renal Center of Excellence, Tulane University Health Sciences Center, New Orleans, Louisiana

<sup>2</sup>Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia

### Abstract

**BACKGROUND**—We tested the hypothesis that *Foxd1*, a transcription factor essential for normal kidney development, is an upstream regulator of the renin–angiotensin system (RAS) during ureteric bud (UB)-branching morphogenesis.

**METHODS**—UB branching, RAS gene, and protein expression were studied in embryonic mouse kidneys. RAS mRNA expression was studied in mesenchymal MK4 cells.

**RESULTS**—The number of UB tips was reduced in *Foxd1*<sup>−/−</sup> compared with that in *Foxd1*<sup>+/+</sup> metanephroi on embryonic day E12.5 ( $14 \pm 2.1$  vs.  $28 \pm 1.3$ ,  $P < 0.05$ ). Quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) demonstrated that renin, angiotensin I-converting enzyme (ACE), and angiotensin (Ang) II receptor type 1 (AT<sub>1</sub>R) mRNA levels were decreased in *Foxd1*<sup>−/−</sup> compared with those in *Foxd1*<sup>+/+</sup> E14.5 metanephroi. Western blot analysis and immunohistochemistry showed decreased expression of AGT and renin proteins in *Foxd1*<sup>−/−</sup> metanephroi compared with that in *Foxd1*<sup>+/+</sup> metanephroi. *Foxd1* overexpression in mesenchymal MK4 cells *in vitro* increased renin, AGT, ACE, and AT<sub>1</sub>R mRNA levels. Exogenous Ang II stimulated UB branching equally in whole intact E12.5 *Foxd1*<sup>−/−</sup> and *Foxd1*<sup>+/+</sup> metanephroi grown *ex vivo* ( $+364 \pm 21\%$  vs.  $+336 \pm 18\%$ ,  $P = 0.42$ ).

**CONCLUSION**—We conclude that Foxd1 is an upstream positive regulator of RAS during early metanephric development and propose that the cross-talk between Foxd1 and RAS is essential in UB-branching morphogenesis.

The metanephric kidney is formed via reciprocal interactions of transcription and growth factors expressed in the metanephric mesenchyme, stroma, and ureteric bud (UB) (1). The stroma is a complex mixture of cell types that do not differentiate into nephrons or UBs. The stroma gives rise to the interstitium in the mature kidney, which contains fibroblasts, lipid-laden interstitial cells, lymphocyte-like cells, pericytes, and extracellular matrix (2,3). Recent studies demonstrated that renal stroma is an essential regulator of both UB-branching morphogenesis and nephrogenesis, and provided important insights into the mechanisms by which the stroma regulates metanephric organogenesis. With respect to UB and UB-derived renal collecting system development, inactivation of a number of genes expressed distinctly

in the stroma in mice is associated with reduced UB branching or medullary hypodysplasia (Table 1).

The critical role of the renin–angiotensin system (RAS) in UB morphogenesis and renal collecting system development is evident from (i) reduced UB branching observed in angiotensinogen (*AGT*<sup>-/-</sup> and angiotensin (Ang) II *AT<sub>2</sub> receptor* (*AT<sub>2</sub>R*)<sup>-/-</sup> mice or during pharmacologic inhibition of Ang II receptor type 1 (AT<sub>1</sub>R) in embryonic metanephroi grown *ex vivo*, and (ii) occurrence of medullary hypoplasia in mice and renal tubular dysgenesis in humans with mutations in *AGT*, *renin*, angiotensin-converting enzyme (*ACE*), or *AT<sub>1</sub>R* genes (Table 1) (4). Using immunohistochemical analysis, we previously demonstrated that AGT and AT<sub>1</sub>R proteins are expressed in both the UB and the surrounding stroma as early as embryonic (E) day E12 in mice (5). Recent studies in renin knock-in reporter mice have demonstrated that juxtaglomerular renin-producing cells originate from the metanephric mesenchyme/stroma on E11–E12, at a time when UB branching is just beginning (6). This raises the intriguing possibility that Ang II can be generated locally in the stroma and then acts in a paracrine manner on the adjacent AT<sub>1</sub>R-expressing UBs to induce branching.

In this work, we tested the hypothesis that *Foxd1*, a forkhead box transcription factor expressed in the stroma, which is essential for normal kidney development (7,8), is an upstream regulator of RAS during UB-branching morphogenesis. We demonstrate that reduced UB branching observed in *Foxd1*<sup>-/-</sup> metanephroi is accompanied by decreased expression of AGT, renin, ACE, and AT<sub>1</sub>R mRNA as well as AGT and renin protein levels. Conversely, *Foxd1* over-expression in mesenchymal cells increases AGT, renin, ACE, and AT<sub>1</sub>R mRNA levels. We propose that the cross-talk between RAS and Foxd1 has an important role in UB-branching morphogenesis.

## METHODS

### Metanephric Organ Culture

*Foxd1*-mutant mice (7) were acquired from Jackson laboratories, Bar Harbor, ME. *Hoxb*<sup>GFP+/-</sup> transgenic mice, which express green fluorescent protein (GFP) exclusively in the UB, were a kind gift from F. Costantini (Columbia University, New York, NY). The day when the vaginal plug was observed was considered to be E0.5. Embryonic metanephroi were dissected from double-transgenic *Foxd1*-mutant;*Hoxb*<sup>GFP+</sup> mice on E11.5 or E12.5 and grown on polycarbonate transwell filters (Corning Costar, Corning, NY, USA, 0.5 μm) inserted into six-well plates containing Dulbecco's modified essential medium/F12 medium (Gibco BRL, Grand Island, NY, USA) and 0.5% fetal bovine serum (FBS) or medium, 0.5% FBS, and Ang II (10<sup>-5</sup> M) for 24 h at 37 °C and 5% CO<sub>2</sub> as previously described (9). The effect of drug treatment was studied in paired kidneys obtained from the same fetus (i.e., the left kidney was incubated with media and the right kidney with Ang II). Time-lapse images of GFP<sup>+</sup> metanephroi from *Foxd1*<sup>+/+</sup>;*Hoxb*<sup>GFP+</sup> (*n* = 4 fetuses) were obtained at dissection on E12.5 and after 24 h of culture, and those of *Foxd1*<sup>-/-</sup>;*Hoxb*<sup>GFP+</sup> embryos were obtained at dissection on E11.5 (*n* = 3 fetuses) or E12.5 (*n* = 4 fetuses) and after 24 h of culture; the number of UB tips was counted at each time point. Images were acquired directly from the plates using an Olympus IX70 inverted phase-contrast microscope

(Pittsburgh, PA, USA), Olympus MagnaFire FW camera (Pittsburgh, PA, USA) and processed with Adobe PhotoShop 7.0.

### Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction

Quantitative real-time SYBR Green RT-PCR (SABiosciences, Frederick, MD) was utilized to determine the expression of renin, ACE, and Ang AT<sub>1</sub>R mRNA levels in *Foxd1*<sup>-/-</sup> compared with *Foxd1*<sup>+/+</sup> E14.5 metanephroi. The AT<sub>1</sub>R primers used detect the AT<sub>1A</sub>R subtype. The quantity of target mRNA expression was normalized by that of GAPDH mRNA expression. E14.5 metanephroi were pooled from *Foxd1*<sup>-/-</sup> and *Foxd1*<sup>+/+</sup> fetuses, and two pooled RNA samples per *Foxd1* genotype were analyzed in triplicate in each run. PCR reaction was performed three times.

### Western Blot Analysis

Mouse embryonic kidneys were pooled and homogenized in cold lysis buffer containing a cocktail of enzyme inhibitors. The samples were centrifuged, and the supernatants containing proteins (30 µg/lane) were resolved on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. After blocking nonspecific binding, the membranes were incubated with a rabbit anti-AGT polyclonal antibody (1:100, generously provided by J. Chan, University of Montreal), an antirenin rabbit polyclonal antibody (Santa Cruz, Dallas, TX, USA sc-22752, 1/200), a rabbit polyclonal anti-Foxd1 antibody (Santa Cruz, sc-133586, 1:200), and an anti-β-actin monoclonal antibody (Sigma, St Louis, MO; 1:5000) at room temperature for 1 h. After washes in phosphate-buffered saline/Tween, the nitrocellulose membrane was exposed for 1 h at room temperature to the secondary antibody. Immunoreactive bands were visualized using the enhanced chemiluminescence detection system (ECL, Amersham, NJ).

### Immunohistochemistry for AGT and Renin

Immunolocalization of AGT and renin proteins was performed in *Foxd1*<sup>-/-</sup> and *Foxd1*<sup>+/+</sup> E17.5 metanephroi (*n* = 3 per group). Immunostaining was performed with the immunoperoxidase technique using the Vectastain Elite kit (Vector Laboratories, Burlingame, CA). A renin rabbit polyclonal antibody was generously provided by Ariel Gomez, University of Virginia, and used at a dilution of 1:500 (ref. 10). Specificity of immunostaining was documented by the elimination of immunoreactivity after omission of the primary antibody. Spatial colocalization of AGT immunoreactivity in the proximal tubules was achieved by co-staining with fluorescein isothiocyanate-conjugated lotus tetragonolobus lectin agglutinin (LTA; Vector Laboratories, 1:100). The number of LTA-positive tubular structures was counted in a blinded manner per kidney section (*n* = 3 mice per genotype, two sections per kidney). The number of AGT-positive structures in LTA-positive tubules was counted by colocalization of red staining (AGT) with green staining (LTA) in the same kidney sections.

### Foxd1 Overexpression in MK4 Cells

MK4 cells (generously provided by S. Potter, University of Cincinnati) were plated into six-well plates at  $2 \times 10^5$  cells per well and grown overnight in Dulbecco's modified essential

medium high-glucose media with 10% FBS at 37 °C and 5% CO<sub>2</sub> to ~ 70% confluence. The cells were then incubated with 1 µg of Foxd1 expression vector (CMV-BF2;  $n = 3$  wells; a kind gift from Leif Oxburgh, Maine Medical Center Research Institute) (11), with a MOCK plasmid pcDNA<sup>TM</sup>3.1 (Thermo Fisher Scientific, Grand Island, NY, USA), or without Foxd1 expression vector ( $n = 3$  wells) but using Lipofectamine LTX with PLUS mixture (Invitrogen, Grand Island, NY, USA) at 37 °C for 24 h. Non-transfected cells were selectively eliminated by the addition of gentamicin (100 µg/µl per well). Transfected cells were harvested for RNA or protein extraction at ~ 90% confluence. The experiments were performed twice. Protein concentration was measured using a Pierce BCA Protein Concentration Kit (Thermo Scientific). The effect of Foxd1 transfection on Foxd1 protein expression was determined by western blot analysis and on renin, AGT, ACE, and AT<sub>1</sub>R mRNA levels by real-time SYBR Green RT-PCR. All samples were blind-coded for counting. All experiments involving mice were approved by Tulane Institutional Animal Care and Use Committee.

### Statistical Analysis

Data are presented as mean ± SEM. Differences among the treatment groups in mRNA levels and the number of UB tips were analyzed by one-way ANOVA followed by Bonferroni's test. Differences among the treatment groups in protein levels were analyzed by Student's *t*-test. A *P* value <0.05 was considered statistically significant.

## RESULTS

### Effect of Foxd1 Gene Dosage and Ang II on UB Branching

The number of UB tips was reduced in *Foxd1*<sup>-/-</sup>;*Hoxb7*<sup>GFP+</sup> ( $n = 4$  fetuses, eight kidneys) compared with *Foxd1*<sup>+/+</sup>;*Hoxb7*<sup>GFP+</sup> ( $n = 4$  fetuses, eight kidneys) E12.5 metanephroi (14 ± 2.1 vs. 22 ± 1.2,  $P < 0.05$ ; Figure 1). These findings indicate that Foxd1 signaling stimulates early UB branching and are consistent with previous reports that implicate Foxd1 in renal branching morphogenesis (7). To further investigate the functional cross-talk between RAS and Foxd1, we examined the ability of exogenous Ang II to rescue UB morphogenesis in *Foxd1*<sup>-/-</sup> mice. We previously demonstrated that treatment of whole intact E12.5 mouse metanephroi grown *ex vivo* with 10<sup>-5</sup> M Ang II increases the number of UB tips compared with treatment with control media (12). We therefore used the same concentration of Ang II in this study. Following 24 h of *ex vivo* culture, the UB tip number remained reduced in *Foxd1*<sup>-/-</sup> compared with that in *Foxd1*<sup>+/+</sup> kidneys grown in the presence of media (control; Figure 1). Treatment with Ang II increased the UB tip number in both *Foxd1*<sup>-/-</sup> (37 ± 1.8 vs. 28 ± 1.1,  $P < 0.05$ ) and *Foxd1*<sup>+/+</sup> (48 ± 2 vs. 38 ± 1.8,  $P < 0.01$ ) kidneys compared with control (Figure 1). Ang II caused a similar percentage increase in the UB tip number in *Foxd1*<sup>-/-</sup> ( $n = 4$  kidneys) and *Foxd1*<sup>+/+</sup> ( $n = 4$  kidneys) metanephroi after 24 h of culture (135 ± 9% vs. 139 ± 7%,  $P = 0.87$ ). To determine whether there is a true restoration of UB branching in Ang II-treated *Foxd1*<sup>-/-</sup> metanephroi, we investigated the effect of Ang II on UB tip number in kidneys isolated from E11.5 *Foxd1*<sup>-/-</sup> mice and grown *ex vivo* for 24 h with and without Ang II. Although the initial number of UB tips did not differ on E11.5 (3.2 ± 0.3 vs. 3.1 ± 0.6,  $P = 0.8$ ), treatment with Ang II increased the number of UB tips (19 ± 1.4 vs. 14 ± 0.6,  $P < 0.05$ ) compared with the number after treatment with

control media (Figure 1). This effect of Ang II is consistent with the ability of Foxd1 to function upstream of RAS.

### Effect of Foxd1 Gene Dosage on AGT, Renin, ACE, and AT<sub>1</sub>R Gene Expression and on AGT and Renin Protein Expression in the Embryonic Kidney

To determine whether lack of Foxd1 in *Foxd1*<sup>-/-</sup> mice that manifest impaired UB branching downregulates AGT, renin, ACE, and Ang II AT<sub>1</sub>R gene expression in the developing kidney *in vivo*, we measured AGT, renin, ACE, and AT<sub>1</sub>R mRNA levels in *Foxd1*<sup>-/-</sup> and *Foxd1*<sup>+/+</sup> E14.5 mouse metanephroi. Renin (0.23 ± 0.01 vs. 1.0 ± 0, *P*<0.01), AGT (0.61 ± 0.02 vs. 1.0 ± 0, *P*<0.01), ACE (0.37 ± 0.02 vs. 1.0 ± 0, *P*<0.01), and AT<sub>1</sub>R (0.41 ± 0.06 vs. 1.0 ± 0, *P*<0.01) mRNA levels were decreased in *Foxd1*<sup>-/-</sup> metanephroi compared with the levels in *Foxd1*<sup>+/+</sup> metanephroi (Figure 2a). To determine whether the observed decrease in *AGT* and *renin* gene expression in *Foxd1*<sup>-/-</sup> kidneys is accompanied by a reduction in AGT and renin protein levels, we measured AGT and renin protein contents in E14.5 *Foxd1*<sup>-/-</sup> (*n* = 3 pooled samples) and *Foxd1*<sup>+/+</sup> (*n* = 3 pooled samples) metanephroi by western blot analysis. Both AGT (54 ± 6% vs. 100 ± 12%, *P*<0.01) and renin (48 ± 4% vs. 100 ± 11%, *P*<0.01) protein levels were decreased in *Foxd1*<sup>-/-</sup> compared with *Foxd1*<sup>+/+</sup> metanephroi (Figure 2b,c).

To delineate the effect of *Foxd1* gene dosage on the spatial expression of AGT and renin proteins in the embryonic kidney, we mapped the cellular localization of AGT and renin proteins in E17.5 *Foxd1*<sup>-/-</sup> (*n* = 3) and *Foxd1*<sup>+/+</sup> (*n* = 3) metanephroi by immunohistochemistry. Consistent with a smaller surface area of the UB tree observed on E12.5 (Figure 1b), the kidney size was grossly reduced in *Foxd1*<sup>-/-</sup> compared with that in *Foxd1*<sup>+/+</sup> mice on E17.5 (Figure 3a,b). In *Foxd1*<sup>+/+</sup> kidneys, AGT immunoreactivity was observed in tubules that resemble morphologically proximal tubules and in UB branches (Figure 3b). Overall, less AGT immunoreactivity was observed in *Foxd1*<sup>-/-</sup> than in *Foxd1*<sup>+/+</sup> metanephroi, although AGT staining appeared to be present in the same structures as in the wild-type kidneys (Figure 3a,b). The number of AGT-positive structures in the proximal tubules visualized with anti-LTA antibody was lower (10 ± 2.1 vs. 29 ± 4.1, *P*<0.05), whereas the number of LTA-positive proximal tubules was not different (90 ± 8.1 vs. 99 ± 9.5, *P* = 0.50), in *Foxd1*<sup>-/-</sup> compared with *Foxd1*<sup>+/+</sup> metanephroi (Figure 3d,e). These findings suggest that reduced AGT expression in the proximal tubules in *Foxd1*<sup>-/-</sup> metanephroi is not secondary to a decrease in the number of proximal tubules. These findings are consistent with a previous report showing abundant proximal tubules in mice with global *Foxd1* knockout (8). In addition, the number of nephrons on E18.5 in *Foxd1* mutants (on a per-kidney-volume basis) is similar to the number of nephrons present in the wild-type kidney (8). Lack of reduction in the number of LTA-positive proximal tubules in spite of reduced UB branching in *Foxd1* mutants may be explained by the increased ratio of pre-tubular aggregated per UB ampulla (8).

In E17.5 *Foxd1*<sup>+/+</sup> kidneys, renin immunoreactivity is present throughout the length of the afferent arterioles and interlobular and arcuate arteries (Figure 4a,b). In *Foxd1*<sup>-/-</sup> kidneys, renin immunoreactivity is less broad and is confined to a few cells in vascular structures that resemble morphologically afferent arterioles and interlobular and arcuate arteries (Figure

4c,d). Whether the decrease in renin immunostaining is due to a direct effect on renin (or another gene) or due to a general decrease in kidney growth remains to be determined. Collectively, these data suggest that endogenous Foxd1 acts upstream of RAS to increase AGT, renin, ACE, and AT<sub>1</sub>R mRNA expression, as well as AGT and renin protein levels.

### Effect of Foxd1 Overexpression in Mesenchymal Cells on RAS Gene Expression

To determine whether Foxd1 overexpression in renal mesenchymal cells upregulates AGT, renin, ACE, and AT<sub>1</sub>R gene expression, we examined AGT, renin, ACE, and AT<sub>1</sub>R mRNA levels in MK4 cells transfected ( $n = 3$  wells) or not ( $n = 3$  wells) with Foxd1 expression plasmid *in vitro*. The MK4 cell line represents embryonic metanephric mesenchyme undergoing epithelial conversion. Notably, cultured MK4 cells maintain the expression of endogenous AGT, renin, ACE, AT<sub>1</sub>R, and Foxd1 mRNA (Figure 5a). Transfection of MK4 cells with Foxd1 expression plasmid increased Foxd1 protein levels compared with the levels in untransfected cells (Figure 5b). This was accompanied by increased AGT ( $1.3 \pm 0.08$  vs.  $1.0 \pm 0$ ,  $P < 0.05$ ), renin ( $1.3 \pm 0.08$  vs.  $1.0 \pm 0$ ,  $P < 0.05$ ), ACE ( $2.2 \pm 0.3$  vs.  $1.0 \pm 0$ ,  $P < 0.01$ ), and AT<sub>1</sub>R ( $1.3 \pm 0.04$  vs.  $1.0 \pm 0$ ,  $P < 0.01$ ) mRNA levels in transfected compared with untransfected cells (Figure 5c). In contrast, transfection of MK4 cells with a MOCK plasmid ( $n = 3$  wells) did not alter AGT, renin, ACE, or AT<sub>1</sub>R mRNA levels compared with the levels in untransfected cells (Figure 5c). These findings indicate that upregulation of AGT, renin, ACE, or AT<sub>1</sub>R mRNA levels by Foxd1 expression plasmid is not due to unspecific effects. Thus, Foxd1 acts upstream of *AGT*, *renin*, *ACE*, and *AT<sub>1</sub>R* genes to upregulate their expression in embryonic mesenchymal cells.

## DISCUSSION

The present study tested the hypothesis that Foxd1 is an upstream regulator of RAS during UB-branching morphogenesis. Our major findings are as follows: (i) the reduced UB branching observed in *Foxd1*<sup>-/-</sup> metanephroi is accompanied by decreased expression of AGT, renin, ACE, and AT<sub>1</sub>R mRNA as well as AGT and renin protein levels; (ii) *Foxd1* overexpression in mesenchymal cells increases AGT, renin, ACE, and AT<sub>1</sub>R mRNA levels; (iii) treatment with exogenous Ang II causes a similar induction of UB branching in *Foxd1*<sup>-/-</sup> and *Foxd1*<sup>+/+</sup> whole intact metanephroi grown *ex vivo*.

Foxd1 and RAS are both critically important for metanephric kidney organogenesis (7,8,13). In the mouse, Foxd1, a forkhead box transcription factor, is expressed from the onset of UB branching around Pax2-expressing cells of the induced nephrogenic mesenchyme. From E14.5 onward, Foxd1 is localized in the cortical renal stroma, with lower levels present in the medullary stroma (7). *Foxd1*-mutant mice exhibit impaired UB branching, aberrant nephrogenesis, and fused pelvic kidneys, a phenotype reminiscent of the horseshoe kidney, the most common renal fusion anomaly observed in humans (7,8,14). Thus, lack of *Foxd1* causes a defect in the ability of the stroma to support normal UB branching and nephrogenesis.

Foxd1 and RAS are essential for UB-branching morphogenesis. Reduced UB branching is observed in *AGT*<sup>-/-</sup> and Ang II *AT<sub>2</sub>R*<sup>-/-</sup> mice or during pharmacologic inhibition of Ang II AT<sub>1</sub>R in embryonic mouse metanephroi grown *ex vivo* (15,16). Using immunohistochemical

analysis, we previously demonstrated that AGT and AT<sub>1</sub>R proteins are expressed in both the UB and the surrounding stroma as early as E12 in mice (5). Given that renin-producing cells originate from the mesenchyme on E11–E12, at a time when UB branching is just beginning (6), Ang II may be generated locally in the mesenchyme to act in a paracrine manner on the adjacent AT<sub>1</sub>R-expressing UBs to stimulate branching. In accordance with this hypothesis, treatment of E11.5 mouse intact isolated UBs grown in three-dimensional collagen matrix gels with Ang II stimulates UB branching (17). Similarly, AT<sub>1</sub>R present in the stroma may be important in mediating stromal Ang II signaling to stimulate UB branching (5). One possible pathway may involve Ang II-induced stimulation of stromal factor fibroblast growth factor 7 (FGF7) and its coupling with the FGF7 receptor expressed on the UB (18). This possibility is supported by the ability of Ang II to increase bFGF mRNA levels in luteal cells (19).

Potential interactions among AGT, renin, and Foxd1 in the stroma are supported by the findings that *AGT* and *renin* promoters contain a putative binding site for Foxd1 (ref. 20). It has been shown that Foxd1 binds to a hepatocyte nuclear factor 3 (HNF3, a winged helix transcription factor) site to activate transcription (20). As mouse *renin* (GTAAACA, position – 736) and *AGT* (TGCTTGCTAG, position – 758) genes contain a conserved HNF3 site/core sequence and HNF3B stimulates *AGT* gene transcription (21), it may be possible that, as a transcription factor, Foxd1 stimulates the production of AGT, renin, or AT<sub>1</sub>R in the stroma to enhance UB branching. Thus, Foxd1 may act upstream from AGT or renin, and UB-branching defects in Foxd1-mutant mice may be secondary, in part, to dysregulation of the RAS. Reduction in proximal tubule AGT protein levels in *Foxd1*<sup>-/-</sup> kidneys may also be due to disruption of Foxd1-dependent signals that mediate the communication between the stromal and nephrogenic compartments. One potential signal may be stromally expressed  $\beta$ -catenin, reported to regulate the induction of nephrogenic progenitors (22). In support of this possibility, bioinformatic analyses reveal the presence of the consensus T-cell factor-binding sites in the regulatory regions of the AGT gene (23).

Given that *RAS* gene expression was not completely attenuated in the absence of Foxd1, it is possible that Foxd1 forms a complex with other transcription factors and acts indirectly to modulate the RAS gene expression. This possibility is supported by the findings that forkhead transcription factors associate with the Groucho co-repressor (24). In addition, Foxd1 associates with a Smad-binding partner, FAST-2 (25). Notably, initiation of nephron progenitor cell differentiation, normally induced by Smad signaling, is inhibited in *Foxd1*<sup>-/-</sup> kidneys(11).

One mechanism by which RAS can mediate cross-talk between stromal Foxd1 and UB is via Ret. This possibility is supported by the ability of Ang II to induce tyrosine phosphorylation of Ret in whole intact E12.5 mouse metanephroi grown *ex vivo* (17). Our present findings that Ang II stimulates UB branching equally in *Foxd1*<sup>-/-</sup> and *Foxd1*<sup>+/+</sup> mice indicate that Ang II signaling to the UB in *Foxd1* mutants is intact and is consistent with the ability of Foxd1 to function upstream of RAS. Another possibility is that Foxd1-positive stromal cells give rise to renin-producing juxtaglomerular cells (26). This possibility is supported by our present findings of limited expression of renin in maturing renal vasculature in *Foxd1*<sup>-/-</sup> mice.

In summary, the present study demonstrates that genetic inactivation of *Foxd1* in mice downregulates *AGT*, *renin*, *ACE*, and *AT<sub>1</sub>R* gene expression in the developing metanephroi *in vivo*. In contrast, *Foxd1* overexpression in renal mesenchymal cells *in vitro* upregulates the expression of *AGT*, *renin*, *ACE*, and *AT<sub>1</sub>R* genes. Ang II stimulates UB branching equally in *Foxd1*<sup>-/-</sup> and *Foxd1*<sup>+/+</sup> metanephroi grown *ex vivo*. We conclude that Foxd1 is an upstream positive regulator of RAS during early metanephric development and propose that the cross-talk between RAS and *Foxd1* is essential in UB-branching morphogenesis.

## Acknowledgments

This work was supported by NIH Grant DK-71699 (I.Y.). We thank Frank Costantini (Columbia University Medical Center) for providing *Hoxb*<sup>GFP+</sup>, Leif Oxburgh (Maine Medical Center Research Institute) for the Foxd1 expression plasmid, and Shao-Ling Zhang (University of Montreal) for the angiotensinogen antibody.


Disclosure: The authors declare no conflict of interest.

## References


1. Costantini F, Kopan R. Patterning a complex organ: branching morphogenesis and nephron segmentation in kidney development. *Dev Cell*. 2010; 18:698–712. [PubMed: 20493806]
2. Kriz W. Structural organization of the renal medulla: comparative and functional aspects. *Am J Physiol*. 1981; 241:R3–16. [PubMed: 7018270]
3. Lemley KV, Kriz W. Anatomy of the renal interstitium. *Kidney Int*. 1991; 39:370–81. [PubMed: 2062030]
4. Gribouval O, Gonzales M, Neuhaus T. Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. *Nat Genet*. 2005; 37:964–8. [PubMed: 16116425]
5. Iosipiv IV, Schroeder M. A role for angiotensin II AT1 receptors in ureteric bud cell branching. *Am J Physiol Renal Physiol*. 2003; 285:F199–207. [PubMed: 12657564]
6. Sequeira Lopez ML, Pentz ES, Robert B, et al. Embryonic origin and lineage of juxtaglomerular cells. *Am J Physiol Renal Physiol*. 2001; 281:F345–56. [PubMed: 11457727]
7. Hatini V, Huh SO, Herzlinger D, et al. Essential role of stromal mesenchyme in kidney morphogenesis revealed by targeted disruption of Winged Helix transcription factor BF-2. *Genes Dev*. 1996; 10:1467–78. [PubMed: 8666231]
8. Levinson RS, Batourina E, Choi C, et al. Foxd1-dependent signals control cellularity in the renal capsule, a structure required for normal renal development. *Development*. 2005; 132:529–39. [PubMed: 15634693]
9. Yosypiv IV, Schroeder M, El-Dahr SS. AT1R-EGFR crosstalk regulates ureteric bud branching morphogenesis. *J Am Soc Nephrol*. 2006; 17:1005–4. [PubMed: 16495379]
10. Gomez RA, Pentz ES, Jin X, et al. CBP and p300 are essential for renin cell identity and morphological integrity of the kidney. *Am J Physiol Heart Circ Physiol*. 2009; 296:H1255–62. [PubMed: 19252086]
11. Fetting JL, Guay JA, Karolak MJ, et al. FOXD1 promotes nephron progenitor differentiation by repressing decorin in the embryonic kidney. *Development*. 2014; 141:17–27. [PubMed: 24284212]
12. Song R, Spera M, Garrett C, et al. Angiotensin II-induced activation of c-Ret signaling is critical in ureteric bud branching morphogenesis. *Mech Dev*. 2010; 127:21–7. [PubMed: 19961928]
13. Yosypiv IV. Renin-angiotensin system in ureteric bud branching morphogenesis: insights into the mechanisms. *Pediatr Nephrol*. 2011; 26:1499–512. [PubMed: 21359618]
14. Song R, Yosypiv IV. Genetics of congenital anomalies of the kidney and urinary tract. *Pediatr Nephrol*. 2011; 26:353–64. [PubMed: 20798957]
15. Song R, Spera M, Garrett C, et al. Angiotensin II AT2 receptor regulates ureteric bud morphogenesis. *Am J Physiol Renal Physiol*. 2010; 298:F807–17. [PubMed: 20032120]




16. Song R, Van Buren T, Yosypiv IV. Histone deacetylases are critical regulators of the renin-angiotensin system during ureteric bud branching morphogenesis. *Pediatr Res.* 2010; 67:573–8. [PubMed: 20496471]
17. Song R, Preston G, Yosypiv IV. Angiotensin II stimulates *in vitro* branching morphogenesis of the isolated ureteric bud. *Mech Dev.* 2011; 128:359–67. [PubMed: 21820050]
18. Qiao J, Uzzo R, Obara-Ishihara T, et al. FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. *Development.* 1999; 126:547–54. [PubMed: 9876183]
19. Stirling D, Magness RR, Stone R, et al. Angiotensin II inhibits luteinizing hormone-stimulated cholesterol side chain cleavage expression and stimulates basic fibroblast growth factor expression in bovine luteal cells in primary culture. *J Biol Chem.* 1990; 265:5–8. [PubMed: 2294118]
20. Zhang H, Palmer R, Gao X, et al. Transcriptional activation of placental growth factor by the forkhead/winged helix transcription factor Foxd1. *Cur Biol.* 2003; 13:1625–9.
21. Cui Y, Narayanan CS, Zhou J, et al. Exon-I is involved in positive as well as negative regulation of human angiotensinogen gene expression. *Gene.* 1998; 224:97–107. [PubMed: 9931457]
22. Boivin FJ, Sarin S, Lim J, et al. Stromally expressed  $\beta$ -catenin modulates Wnt9b signaling in the ureteric epithelium. *PLoS ONE.* 2015; 10:e0120347. [PubMed: 25803581]
23. Zhou L, Li Y, Hao S, et al. Multiple genes of the renin-angiotensin system are novel targets of wnt/  $\beta$ -catenin signaling. *J Am Soc Nephrol.* 2015; 26:107–20. [PubMed: 25012166]
24. Yaklichkin S, Vekker A, Stayrook S, Lewis M, Kessler DS. Prevalence of the EH1 Groucho interaction motif in the metazoan Fox family of transcriptional regulators. *BMC Genomics.* 2007; 8:201. [PubMed: 17598915]
25. Dou C, Lee J, Liu B, Liu F, Massague J, Xuan S, Lai E. BF-1 interferes with transforming growth factor beta signaling by associating with Smad partners. *Mol Cell Biol.* 2000; 20:6201–11. [PubMed: 10938097]
26. Sequeira Lopez ML, Gomez RA. Development of the renal arterioles. *J Am Soc Nephrol.* 2011; 22:2156–65. [PubMed: 22052047]
27. Miyazaki Y, Oshima K, Fogo A, et al. Bone morphogenic protein 4 regulates the budding site and elongation of the mouse ureter. *J Clin Invest.* 2000; 105:863–73. [PubMed: 10749566]
28. Mendelsohn C, Batourina E, Fung S, et al. Stromal cells mediate retinoid-dependent functions essential for renal development. *Development.* 1999; 126:1139–48. [PubMed: 10021334]
29. Quaggin SE, Schwartz L, Cui S, et al. The basic helix-loop-helix protein Pod1 is critically important for kidney and lung organogenesis. *Development.* 1999; 126:5771–83. [PubMed: 10572052]
30. Schnabel CA, Selleri L, Cleary ML. Pbx1 is essential for adrenal development and urogenital differentiation. *Genesis.* 2003; 37:123–30. [PubMed: 14595835]
31. Lin Y, Liu A, Zhang S, et al. Induction of ureter branching as a response to Wnt-2b signaling during early kidney organogenesis. *Dev Dynamics.* 2001; 222:26–39.
32. Nagata M, Tanimoto K, Fukamizu A, et al. Nephrogenesis and renovascular development in angiotensinogen-deficient mice. *Lab Invest.* 1996; 75:745–53. [PubMed: 8941219]
33. Oliverio MI, Kim HS, Ito M, et al. Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. *Proc Natl Acad Sci USA.* 1998; 95:15496–501. [PubMed: 9860997]
34. Miyazaki Y, Tsuchida S, Fogo A, et al. The renal lesions that develop in neonatal mice during angiotensin inhibition mimic obstructive nephropathy. *Kidney Int.* 1999; 55:1683–95. [PubMed: 10231430]
35. Yosypiv IV, Boh MK, Spera M, et al. Downregulation of Spry-1, an inhibitor of GDNF/Ret, as a mechanism for angiotensin II-induced ureteric bud branching. *Kidney Int.* 2008; 74:1287–93. [PubMed: 18650792]
36. Nishimura H, Yerkes E, Hohenfellner K, et al. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. *Mol Cell.* 1999; 3:1–10. [PubMed: 10024874]
37. Oshima K, Miyazaki Y, Brock JW, et al. Angiotensin type II receptor expression and ureteral budding. *J Urol.* 2001; 166:1848–52. [PubMed: 11586245]




**Figure 1.** Effect of genetic inactivation of *Foxd1* and treatment with angiotensin (Ang) II on ureteric bud (UB) branching in mouse metanephroi. Time-lapse images of *Foxd1*<sup>-/-</sup>/*Hoxb7*<sup>GFP+</sup> kidneys isolated on E11.5 and grown *ex vivo* for 24 h in the presence of Ang II (10<sup>-5</sup> M) or media (control; **a**). (**b**) Time-lapse images of *Foxd1*<sup>+/-</sup>/*Hoxb7*<sup>GFP+</sup> and *Foxd1*<sup>+/+</sup>/*Hoxb7*<sup>GFP+</sup> metanephroi isolated on E12.5 and grown *ex vivo* in the presence of Ang II or media (control; **b**). UBs are visualized with GFP (green; **a,b**). Bar graph showing the number of UB tips in *Foxd1*<sup>-/-</sup>/*Hoxb7*<sup>GFP+</sup> metanephroi on E11.5 and after 24 h of culture. \**P*<0.05 vs. media (**c**). Bar graph showing the effect of Ang II or media (control) on UB tip number in E12.5 *Foxd1*<sup>-/-</sup>/*Hoxb7*<sup>GFP+</sup> and *Foxd1*<sup>+/+</sup>/*Hoxb7*<sup>GFP+</sup> metanephroi after 24 h of *ex vivo* culture (**d**; \**P*<0.01 vs. *Foxd1*<sup>-/-</sup>+media; #*P*<0.05 vs. *Foxd1*<sup>-/-</sup>+media). Numbers on (**a,b**) indicate the number of UB tips. GFP, green fluorescent protein.

**Figure 2.**

Effect of genetic inactivation of *Foxd1* on RAS gene and protein expression in the E14.5 metanephroi. Bar graph showing the effect of genetic inactivation of *Foxd1* on AGT, renin, ACE, and Ang II AT<sub>1</sub>R mRNA expression factored per expression of GAPDH mRNA in the mouse kidney as determined by qRT-PCR (**a**; *Foxd1*<sup>+/+</sup> kidney values are normalized to 1, and data are presented as relative-fold difference. \**P*<0.05 vs. *Foxd1*<sup>+/+</sup>). Western blots (30 μg total protein/lane) showing angiotensinogen (AGT) and renin protein expression in *Foxd1*<sup>+/+</sup> and *Foxd1*<sup>-/-</sup> kidneys (**b**). Bar graph showing that AGT/ $\beta$ -actin and renin/ $\beta$ -actin ratios are decreased in *Foxd1*<sup>-/-</sup> compared with *Foxd1*<sup>+/+</sup> metanephroi (**c**; \**P*<0.05 vs. *Foxd1*<sup>+/+</sup>). ACE, angiotensin I-converting enzyme; Ang, angiotensin.




**Figure 3.** Immunolocalization of angiotensinogen (AGT) protein in the embryonic *Foxd1*<sup>+/+</sup> and *Foxd1*<sup>-/-</sup> kidneys on E17.5. AGT immunoreactivity (brown staining) is present in the tubules that resemble morphologically proximal tubules (PT) and in UB branches (a,b). Control section, where the addition of the primary antibody was omitted, demonstrates no brown staining (c). Spatial co-localization of FITC-conjugated AGT (red) and lotus tetragonolobus lectin agglutinin (LTA, green) immunoreactivity in the proximal tubules in *Foxd1*<sup>+/+</sup> and *Foxd1*<sup>-/-</sup> metanephroi (d). Bar graph showing the number of AGT- and LTA-positive structures in *Foxd1*<sup>-/-</sup> and *Foxd1*<sup>+/+</sup> metanephroi (e; \**P*<0.05 vs. *Foxd1*<sup>+/+</sup>). FITC, fluorescein isothiocyanate. Scale bar = 100  $\mu$ m.



**Figure 4.**

Immunolocalization of renin protein in the fetal *Foxd1*<sup>+/+</sup> and *Foxd1*<sup>-/-</sup> kidneys on E17.5. Renin immunoreactivity (brown staining) is present in the afferent arterioles (AA) and interlobular (IA) and arcuate (ArA) arteries (**a,b**). In *Foxd1*<sup>-/-</sup> kidneys, renin immunoreactivity is confined to a few cells in the vascular structures that resemble afferent arterioles and interlobular and arcuate arteries (**c,d**; scale bar = 100  $\mu$ m).



**Figure 5.** Mesenchymal (MK4) cells cultured *in vitro* express angiotensinogen (AGT, 280 bp), renin (Ren, 600 bp), angiotensin-converting enzyme (ACE, 614 bp), AT<sub>1</sub>R (603 bp), and Foxd1 (398 bp) mRNA (**a**; Kid—E14.5 mouse kidney). Western blot (30 μg total protein/lane) showing increased Foxd1 protein levels in MK4 cells transfected with Foxd1 expression vector compared with control untransfected cells (**b**). Bar graph shows the effect of Foxd1 overexpression in MK4 cells (Foxd1) on renin (Ren), AGT, ACE, and AT<sub>1</sub>R mRNA expression as determined by qRT-PCR (**c**; Con, control MK4 cells not transfected with Foxd1 vector. MOCK, MK cells transfected with a MOCK plasmid that does not express Foxd1). \* $P < 0.05$  vs. control. ACE, angiotensin I-converting enzyme.

**Table 1**

Effect of stromal factors on UB-branching morphogenesis.

Gene	Renal phenotype	UB phenotype	References
<i>Foxd1</i> <sup>-/-</sup>	Hypoplasia	Reduced branching	(6)
<i>FGF7</i> <sup>-/-</sup>	Hypoplasia	Reduced branching/size	(17)
<i>BMP4</i> <sup>-/-</sup>	Hypoplasia, dysplasia, hydronephrosis, bifid ureters	Shorter UB, ectopic UB budding	(27)
<i>RARβ2</i> <sup>-/-</sup> / <i>RARα</i> <sup>-/-</sup>	Hypoplasia	Reduced branching	(28)
<i>Pod1</i> <sup>-/-</sup>	Hypoplasia, dysplasia	Decreased branching, aberrant patterning	(29)
<i>Pbx1</i> <sup>-/-</sup>	Hypoplasia	Decreased branching,	(30)
<i>Wnt2b</i> <sup>-/-</sup>	—	Increased UB branching and surface area	(31)
<i>p57<sup>Kip2</sup></i> <sup>-/-</sup>	Medullary, dysplasia		(19)
<i>AGT</i> <sup>-/-</sup>	Thin medulla, atrophic papilla, hydronephrosis, decreased UB branching		(14,32)
<i>AT<sub>1</sub>R</i> <sup>-/-</sup>	Atrophic papilla, hydronephrosis, decreased ureteral peristalsis		(33,34)
AT <sub>1</sub> R inhibition	Atrophic papilla	Decreased UB branching	(35)
<i>AT<sub>2</sub>R</i> <sup>-/-</sup>	Hypoplasia, dysplasia	Ectopic UB budding, decreased UB branching	(26,21,36,37)

UB, ureteric bud.